Acute myeloid leukemia (AML) is a cancer that starts in the bone marrow, and spreads to blood, and other parts of the body. Generally, AML develops in white blood cells forming cells, and sometimes it develops in other types of blood-forming cells as well. Changes/mutations in the DNA in bone marrow cells results in formation of leukemia cells. Moreover, most of the DNA mutations causing AML occur during a person’s lifetime rather than genetic inheritance. AML is also known by different names such as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia.

Market Drivers and Restraints:

• Although AML is considered a rare disease, it is still the most commonly occurring blood cancer and accounts for only one percent of all cancers.
• According to American Cancer Society (ASC), there were ~60,000 cases of leukemia were diagnosed in the U.S. in 2022, out of which 20,050 new cases of acute myeloid leukemia (AML) are expected. This is expected to support the growth of global acute myeloid leukemia treatment market. 
• Research and development and successful product launches are expected to support global acute myeloid leukemia treatment market growth over the forecast period. For instance, Rigel Pharmaceuticals, Inc. received US FDA approval for Rezlidhia (Olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. 

However, high treatment costs, and difficulty in managing the disease is expected to hamper growth of the market over the forecast period.   

Global Acute Myeloid Leukemia Treatment Market accounted for US$ 976.1 Mn in 2021 and is expected to witness a CAGR of 11.9% over the forecast period (2022-2030) to reach US$ 2,685.1 Mn by 2030

Competitive Landscape:

The global acute myeloid leukemia treatment market is fairly fragmented with multinational corporations and smaller companies operating in the industry. Novel therapies such as targeted therapy, and immuno-therapy have provided more robust and effective treatment options for acute myeloid leukemia over the past few years. 
We have employed tools and techniques such as PEST analysis, SWOT analysis, PORTER’s analysis, and BCG matrix to provide competitive and market intelligence.

Some of the prominent players operating in the market are:

• Jazz Pharmaceuticals
• Pfizer, Inc.
• AstraZeneca
• Novartis AG
• Takeda Pharmaceutical Company
• AbbVie Inc.
• Bristol Myers Squibb
• Daiichi Sankyo
• Rafael Pharmaceuticals Inc.
• Agios Pharmaceuticals
• Rigel Pharmaceuticals, Inc.

Segments Covered in the Global Acute Myeloid Leukemia Treatment Market Report:

The global acute myeloid leukemia treatment market is segmented based on treatment type, distribution channel, region as follows:

• Treatment Type (Revenue, USD Million; 2022–2030)
  • Chemotherapy
  • Targeted Therapy
  • Others
• Distribution Channel (Revenue, USD Million; 2022–2030)
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies
• Region (Revenue, USD Million; 2022–2030)
  • North America 
    • U.S.
    • Canada
  • Europe 
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific 
    • China
    • Japan
    • South Korea
    • India
    • ASEAN
    • Rest of APAC
  • Latin America 
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa 
    • Saudi Arabia
    • UAE
    • Rest of MEA